Ph.D. in health care management and economics, The Wharton School; M.P.P. in health policy, The Johns Hopkins University; A.B. in molecular biology and public policy, Princeton University
Andrew Mulcahy is a policy researcher and associate director of the Economics, Sociology, and Statistics Department at the RAND Corporation; he is also a member of the Pardee RAND Graduate School faculty.
His key research areas are prescription drugs, payment for health care services and drugs, and policy evaluation in general and particularly evaluation of Affordable Care Act (ACA) provisions. He routinely uses large-scale health care claims and transactional data in his research.
Mulcahy leads projects using claims data to evaluate components of the ACA including the dependent coverage, coverage expansion, and Medicaid primary care payment increase provisions. In the area of payment, Mulcahy's recent research focuses on the accurate valuation of services under the Resource-Based Relative Value Scale system used by Medicare and many other payers to pay practitioners. In prescription drugs, Mulcahy is the lead author on a set of RAND Perspectives outlining key policy issues around the 340B Drug Discount Program and biosimilars.
Mulcahy's portfolio also includes analyses of medical care in California's workers' compensation system and an assessment of the U.S. blood system. More broadly, Mulcahy's research at RAND has touched on policy issues around specialty drugs, value in health care, and incentives for innovation in health.
Mulcahy earned his Ph.D. from the University of Pennsylvania's Wharton School Health Care Management and Economics program, his M.P.P. at the Johns Hopkins University with a concentration in health policy, and his A.B. in molecular biology and public policy at Princeton University.
